Comprehensive real-world utilization, treatment trajectories, and outcomes of immune checkpoint inhibitors across cancer types: the multicenter FAIR-ICI cohort
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, yet evidence on their utilization, treatment trajectories, and effective